Lantern Pharma Quote - LTRN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

3.25

Bid

3.00

Ask

3.25

Volume

38,244

3.10 Day's Range 3.41

2.79 52 Week Range 11.99

Market Cap

35.05M

Previous Close

3.177

Open

3.2139

Last Trade

100

3.25

(formt)

Last Trade Time

Financial Volume

US$ 122,144

VWAP

3.1938

Average Volume (3m)

55,835

Shares Outstanding

10,784,725

Dividend Yield

PE Ratio

-2.11

Earnings Per Share (EPS)

-1.48

Revenue

Net Profit

-15.96M

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

Wilmington, Delaware, USA

Founded

Lantern Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LTRN. The last closing price for Lantern Pharma was US$3.18. Over the last year, Lantern Pharma shares have traded in a share price range of US$ 2.79 to US$ 11.99.

Lantern Pharma currently has 10,784,725 shares outstanding. The market capitalization of Lantern Pharma is US$34.26 million. Lantern Pharma has a price to earnings ratio (PE ratio) of -2.11.

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung...

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. Fast Track Designation for LP-184 recognizes TNBC...

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

The Phase 1b clinical trial design presented at SNO2024 combines LP-184 (STAR-001) with spironolactone to potentially enhance therapeutic response in recurrent glioblastoma (GBM) patients...

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months U.S. clinical sites...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.37	-10.2209944751	3.62	3.62	3.1	68489	3.37669618	CS
4	0.26	8.69565217391	2.99	4.88	2.8	81100	3.54333098	CS
12	-0.59	-15.3645833333	3.84	4.88	2.79	55835	3.48495505	CS
26	-1.36	-29.5010845987	4.61	5.1	2.79	55514	3.81730202	CS
52	-0.89	-21.4975845411	4.14	11.99	2.79	125140	6.29565414	CS
156	-4.22	-56.4926372155	7.47	11.99	2.38	68616	5.92081915	CS
260	-11.91	-78.562005277	15.16	24.84	2.38	75167	9.50367141	CS

LTRN - Frequently Asked Questions (FAQ)

What is the current Lantern Pharma share price?

The current share price of Lantern Pharma is US$ 3.25

How many Lantern Pharma shares are in issue?

Lantern Pharma has 10,784,725 shares in issue

What is the market cap of Lantern Pharma?

The market capitalisation of Lantern Pharma is USD 34.26M

What is the 1 year trading range for Lantern Pharma share price?

Lantern Pharma has traded in the range of US$ 2.79 to US$ 11.99 during the past year

What is the PE ratio of Lantern Pharma?

The price to earnings ratio of Lantern Pharma is -2.11

What is the reporting currency for Lantern Pharma?

Lantern Pharma reports financial results in USD

What is the latest annual profit for Lantern Pharma?

The latest annual profit of Lantern Pharma is USD -15.96M

What is the registered address of Lantern Pharma?

The registered address for Lantern Pharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

Which industry sector does Lantern Pharma operate in?

Lantern Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MYSZMy Size Inc	US$ 4.2001 (211.12%)	120.01M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	76.64M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	33.95M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.61k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	120.4M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.32M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	305.1M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	292.16M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	287.21M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	277.63M